ImetelChat

https://seekingalpha.com/instablog/2368 ... veryone-go

Bridge confirms that GERN is withholding the Mayo data. Also that they are doing no work on improving imet or imet delivery systems.

Yes, the priests were horrified when smallpox vaccine let some children "unnaturally" live to adulthood, and they've moaned at every advance since. (Read about Ethan Allan's fight with the clergy on vaccination...) Since I was immortalizing cells with vectors in 2001, I think you're a little out of ...

Kara, Geron actually has at least one patent relating to 6-thio-G... this is just another issue that makes people who follow GERN lose SAN points. The specific MOAs of imet and 6-thio-G are very different, maybe they could be used in combo? With all the GERN patents, why is Scarlett constantly tryin...

>"MF may get approved based on historical data." Yes, that has always been a major hope here (maybe the principal hope, given the competition and timeline in MDS). But it can't happen before the company at least talks to the FDA in 2020. There is plenty of time to order a short oligo from a commerci...

I agree, this is somewhat encouraging. They probably don't have useful historical controls right now because of the differences between different hospitals' protocols and generally bad databases (HIPAA didn't help the already-backwards hospital medical databases). But that doesn't that the necessary...

I keep seeing posts on YHOO and Seeking Alpha from people that "can't get full text of X paper", or even "I can't post the abstract to this paper".

Sci-hub solved these problems long ago, here's the link:

https://whereisscihub.now.sh/

The issue with Janssen as an imetelstat supplier is cost, not quantity. Any commercial supplier would give a better deal (kind of nasty of Janssen to charge high prices for their stockpile of a drug that they are just discarding anyway, but there it is). Again, it's the medical organization "EHA", n...

So has anyone here read this?

You can bet that JNJ read the 2015 papers.

It's the EHA, not the EMA. One tries to cure heme diseases, the other protects pharma cartel profits... try to keep them straight ;) Yes, this is the best-case scenario. IF the abstract suggests durable effectiveness, and IF we hear from Rizo instead of having the entire presentation in stuttervisio...

kara, neither of the Phase 2 trials have placebo arms IIRC. They are using "historical controls", which are very poor as different hospitals keep records differently and the patient groups may not be comparable. The MF trial does have some comparison available between the two dose arms, as the low-d...

I'm all in favor of market-based CEO compensation. I remember the hilarity that ensued when Ben&Jerry tried to hire a "CEO" for one-tenth the market rate (they ended up paying the market rate after all, big surprise). But that doesn't mean that stockholders can just go to sleep while a long-term CEO...

This is a bit premature, but this is a 2018 paper on Phase 3 success rates broken down by category: https://academic.oup.com/biostatistics/article/20/2/273/4817524 Obviously Geron has some special factors (e.g. the large number of previous failed trials), but at least knowing the average success rat...

Thanks Smuggie, interesting stuff... I would have expected options to work better as incentives, at least on CEOs that are below retirement age and still have active lifespan remaining. The good news at GERN, if there is any, is that the Janssen crew knows more about the MOA than anyone else. That d...

@muskateer:

https://www.fda.gov/drugs/developmentap ... efault.htm

Not only does the new FDA director know what a telomere is, he knows that there are multiple telomerase-inhibiting drugs that have already been used clinically since the 1990s, e.g. 6-thio-G, AZT, AZA, etc. etc.... something which GERN enthusiasts keep trying to ignore. http://www.smbc-comics.com/co...

JNJ may think that these older, better-tested drugs are "competitors"... but I see them as potential combos. The FDA hates anything that doesn't fit the mono or at best duo therapy model... but if you throw three selected drugs at each MOA, you can use each one at a less toxic level AND keep the can...

Correction, the ARGX trial used AZA. The basic point stands, there are many TI drugs already in use for other purposes, and JNJ may not feel that they have to own one.

Board votes make a CEO. That's all there is to it, and that's why Scarlett grabbed the Chairman post. As far as Scarlett "working 11 to 12 hours a day"... you're going far beyond any evidence. Listen to the old CCs, Olivia has to remind him of basic facts like trial dates. There are arguments for ow...

Imet is not the only telomerase inhibitor. As everyone with any familiarity with this field should know, AZT was the first telomerase inhibitor, followed by its other anti-retrotranscriptase cousins (e.g. ddI). Those who keep saying that "imetelstat is the only telomerase inhibitor tested in humans"...